Nektar Therapeutics (NKTR) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$35.0 million.
- Nektar Therapeutics' Income from Continuing Operations rose 558.33% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 3263.14%. This contributed to the annual value of -$119.0 million for FY2024, which is 5689.72% up from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' Income from Continuing Operations is -$35.0 million, which was up 558.33% from -$39.2 million recorded in Q2 2025.
- Nektar Therapeutics' Income from Continuing Operations' 5-year high stood at $7.2 million during Q4 2024, with a 5-year trough of -$159.1 million in Q2 2022.
- For the 5-year period, Nektar Therapeutics' Income from Continuing Operations averaged around -$74.5 million, with its median value being -$52.4 million (2024).
- As far as peak fluctuations go, Nektar Therapeutics' Income from Continuing Operations tumbled by 5689.88% in 2021, and later surged by 11719.15% in 2024.
- Quarter analysis of 5 years shows Nektar Therapeutics' Income from Continuing Operations stood at -$146.9 million in 2021, then soared by 54.66% to -$66.6 million in 2022, then skyrocketed by 36.82% to -$42.1 million in 2023, then soared by 117.19% to $7.2 million in 2024, then plummeted by 583.66% to -$35.0 million in 2025.
- Its Income from Continuing Operations stands at -$35.0 million for Q3 2025, versus -$39.2 million for Q2 2025 and -$46.4 million for Q1 2025.